Sun Pharma Showcases Major Research Advancements at 2026 AAD Annual Meeting At the 2026 AAD Annual Meeting, Sun Pharma presents 14 abstracts, showcasing advancements in the treatment of alopecia areata, psoriasis, and acne. The company emphasizes patient-centered care through meaningful scientific data.

Sun Pharma Showcases Major Research Advancements at 2026 AAD Annual Meeting #India #Mumbai #ILUMYA #Sun_Pharma #LEQSELVI

Sun Pharma's ILUMYA Receives FDA Review for Psoriatic Arthritis Treatment Expansion Sun Pharma has announced that the FDA has accepted its application for ILUMYA, aiming to expand treatment options for adults with psoriatic arthritis, adding to its existing psoriasis indications.

Sun Pharma's ILUMYA Receives FDA Review for Psoriatic Arthritis Treatment Expansion #USA #Princeton #ILUMYA #Sun_Pharma #Psoriatic_Arthritis

Sun Pharma Unveils New Findings on Dermatology and Immunology Products at Winter Clinical Miami 2026 At the 2026 Winter Clinical in Miami, Sun Pharma presents significant data across its dermatology and immunology offerings, showcasing innovations for patient care.

Sun Pharma Unveils New Findings on Dermatology and Immunology Products at Winter Clinical Miami 2026 #United_States #Aventura #ILUMYA #Sun_Pharma #Winlevi

Sun Pharma Launches SUNday Campaign for Everyday Skin Cancer Awareness and Care SUNday, a new initiative by Sun Pharma, aims to promote continuous awareness and support for skin cancer care, reflecting everyday realities.

Sun Pharma Launches SUNday Campaign for Everyday Skin Cancer Awareness and Care #India #Mumbai #Skin_Cancer #Sun_Pharma #SUNday

Sun Pharma Launches UNLOXCYT™, A New Treatment for Advanced Skin Cancer Sun Pharmaceutical Industries has introduced UNLOXCYT™, a new option for treating advanced cutaneous squamous cell carcinoma in the U.S., offering significant benefits for patients.

Sun Pharma Launches UNLOXCYT™, A New Treatment for Advanced Skin Cancer #United_States #Princeton #Sun_Pharma #UNLOXCYT #aCSCC

Sun Pharma Welcomes Jeremy Allen as New VP of Corporate Affairs for North America Sun Pharmaceutical Industries has appointed Jeremy Allen as the Vice President of Corporate Affairs for North America. He will lead key policy initiatives and strengthen stakeholder engagement in the region.

Sun Pharma Welcomes Jeremy Allen as New VP of Corporate Affairs for North America #USA #Princeton,_NJ #Corporate_Affairs #Sun_Pharma #Jeremy_Allen

Sun Pharma Launches LEQSELVI for Severe Alopecia Areata Treatment in the U.S. Sun Pharmaceutical Industries has announced the U.S. launch of LEQSELVI, a new treatment option for adults with severe alopecia areata. This breakthrough offers hope for effective hair regrowth.

Sun Pharma Launches LEQSELVI for Severe Alopecia Areata Treatment in the U.S. #United_States #Princeton #Alopecia_Areata #Sun_Pharma #LEQSELVI

Richard Ascroft Takes the Helm as CEO of Sun Pharma North America Sun Pharma appoints Richard Ascroft as CEO for North America. With over 30 years of industry experience, he aims to enhance the company's innovative portfolio.

Richard Ascroft Takes the Helm as CEO of Sun Pharma North America #United_States #North_America #Princeton #Sun_Pharma #Richard_Ascroft

Sun Pharma Receives FDA Approval for LED BLU-U® Blue Light Therapy for Actinic Keratosis Sun Pharma's LED BLU-U® device gains FDA approval for treating actinic keratosis, enhancing patient comfort with new design features.

Sun Pharma Receives FDA Approval for LED BLU-U® Blue Light Therapy for Actinic Keratosis #India #Mumbai #Sun_Pharma #BLU-U #Actinic_Keratosis

Sun Pharma and Moebius Medical Publish New Findings on MM-II for Osteoarthritis Pain Management Sun Pharma and Moebius Medical unveil two pivotal publications on MM-II, exploring pain relief in knee osteoarthritis and its unique mechanism of action.

Sun Pharma and Moebius Medical Publish New Findings on MM-II for Osteoarthritis Pain Management #India #Mumbai #Sun_Pharma #Moebius_Medical #MM-II

Sun Pharma Acquires Checkpoint Therapeutics to Enhance Oncology Offerings Sun Pharma's acquisition of Checkpoint Therapeutics will enable better access to UNLOXCYT™, the first FDA-approved treatment for advanced skin cancer.

Sun Pharma Acquires Checkpoint Therapeutics to Enhance Oncology Offerings #India #Mumbai #Sun_Pharma #Checkpoint #UNLOXCYT

ILUMYA® Proves Effective in Treating Moderate-to-Severe Nail Psoriasis: Insights from AAD 2025 Conference Recent research showcases the effectiveness of ILUMYA® (tildrakizumab-asmn) in alleviating nail psoriasis symptoms in a significant patient cohort. The study highlights its promising results presented at the 2025 AAD Conference.

ILUMYA® Proves Effective in Treating Moderate-to-Severe Nail Psoriasis: Insights from AAD 2025 Conference #USA #Princeton #Psoriasis #ILUMYA #Sun_Pharma